Skip to content

Expressions of Interest now invited for the London Region I AI Regulatory Sandbox.

Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at Whitehouse Communications, signposts a new opportunity for those in the MedTech sector incorporating AI into their devices. AI medical device manufacturers and London-based NHS providers are being invi

Expressions of Interest now invited for the London Region I AI Regulatory Sandbox.
Published: | 1 min read
Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at Whitehouse Communications, signposts a new opportunity for those in the MedTech sector incorporating AI into their devices.

AI medical device manufacturers and London-based NHS providers are being invited to submit an Expression of Interest to participate in a programme to support the evaluation of AI-enabled medical devices in real-world NHS settings. Further information, including eligibility criteria and application details, is available in the call for applications.

Earlier this year, medical device regulator, the Medicines and Healthcare Devices Regulatory Agency (MHRA) said that patients across London would benefit from faster access to innovative, AI‑powered healthcare technologies, as the agency in partnership with NHS England (London) and the London Health Innovation Networks (HINs), as it announced a new regulatory sandbox.

The initiative, known as London Region I, is intended to create a real-world environment to safely deploy AI-enabled medical devices while generating additional evidence of benefit across NHS settings, helping ensure patients can access new technologies earlier while maintaining the highest standards of safety.

By bringing together regulators, healthcare providers and innovators, the sandbox provides a controlled environment so cutting-edge technologies can be safely and securely deployed. The programme will support delivery of the NHS 10 Year Health Plan by enabling faster adoption of technologies that improve patient outcomes, expand access to care, and reduce health inequalities.

Up to 10 AI medical device manufacturers will be selected to participate in the initial phase, working alongside NHS providers across London to deploy technologies in live clinical settings under MHRA oversight.

By enabling controlled, outcomes-based deployment, the sandbox aims to generate robust real-world evidence on safety and effectiveness while supporting a clearer, more predictable route to wider adoption.

The programme will support collaboration between providers and innovators, helping to match technologies with real system needs and enabling rapid, evidence-led deployment in practice.

The Author used AI in preparing this article. Comments upon or questions about this article can be addressed to chris.whitehouse@whitehousecomms.com.

Sign up to our newsletter

The week's biggest stories from this industry, direct to your inbox.

Personal information

More in Insights

See all
Holistic scientific frameworks for real-world use

Holistic scientific frameworks for real-world use

/

More from Oliver Johnson

See all
Holistic scientific frameworks for real-world use

Holistic scientific frameworks for real-world use

/

From our partners

Sponsored content
Driving innovation in medical motion control

Driving innovation in medical motion control

Whether it’s the smooth articulation of a surgical robot, the precise positioning of an imaging system, or the reliable, repeatable movement inside a laboratory instrument, motion control plays a key role in modern medical devices. Despite this, however, it is often one of the most complex aspects o

/